In Japan, innovative technology add-on payments are granted for devices with significant clinical benefits that exceed existing technologies. Manufacturers apply through MHLW, providing robust evidence of safety, efficacy, & cost-effectiveness. Chuikyo reviews the application, and if approved, the device receives premium reimbursement... Read More
Japan’s reimbursement system emphasizes cost containment, centralized decision-making, and strict evaluation by MHLW and Chuikyo. It uses the NHI fee schedule for standardized pricing. Unlike the U.S. or EU, Japan often requires separate classification for innovative devices and rigorous cost-effectiveness analysis. Annual... Read More
Japan handles medical devices with multiple indications by evaluating each indication separately for reimbursement under the NHI system. MHLW & Chuikyo assess the clinical efficacy, safety, and cost-effectiveness for all approved indications. Pricing and classification may differ depending on the indication’s value,... Read More
The appeal process for denied reimbursement applications in Japan involves resubmitting the application with additional evidence to address MHLW or Chuikyo concerns. Manufacturers must provide stronger clinical, safety, or cost-effectiveness data. Engaging with local agents or consultants is common to navigate the... Read More
Japan defines functional categories for reimbursement based on a device’s clinical purpose, technological characteristics, and therapeutic application. These categories group devices with similar functions to standardize evaluation and pricing under the NHI system. New or innovative devices may require unique categories, subject... Read More
Documentation needed for medical device reimbursement in Japan includes regulatory approval, clinical trial data, safety & efficacy evidence, cost-effectiveness analysis, comparison with existing devices, and detailed product specifications. Additional materials like economic evaluations, post-market surveillance plans, and marketing authorization are required for... Read More
Japan’s reimbursement system evaluates imported medical devices similarly to domestic ones, requiring regulatory approval from PMDA & submission to MHLW for reimbursement. Imported devices must demonstrate safety, efficacy, & cost-effectiveness. Local agents often assist with compliance, market entry, & documentation. Pricing may... Read More
A local agent in Japan’s reimbursement process acts as a liaison for foreign manufacturers, facilitating regulatory approvals, reimbursement applications, & communication with MHLW & Chuikyo. They assist with documentation, ensure compliance with local standards, & support market access strategies. Their expertise is... Read More
Japan reimburses diagnostic medical devices under the NHI system, based on evaluations by MHLW & Chuikyo. Devices must demonstrate clinical accuracy, safety, cost-effectiveness, & healthcare utility. Reimbursement is determined through classification, pricing comparisons, or cost-based methods. Innovative diagnostics may receive premium pricing... Read More
Common challenges with reimbursement in Japan include lengthy approval timelines, stringent evidence requirements, navigating complex regulatory & reimbursement processes, & obtaining premium pricing for innovative devices. Aligning with NHI standards, addressing cost-effectiveness concerns, & adapting to periodic fee schedule revisions can also... Read More